Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial
- DOI
- 10.1002/alz.70416
- Published
- 2025-06
- Container
- Alzheimer's & Dementia
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1002/alz.70416,
title = {Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial},
author = {Jeffrey M. Burns and Jill K. Morris and Eric D. Vidoni and Heather M. Wilkins and In‐Young Choi and Phil Lee and Suzanne L. Hunt and Jonathan D. Mahnken and William M. Brooks and Rebecca J. Lepping and Aditi Gupta and Russell Esterline and Jan Oscarsson and Russell H. Swerdlow},
year = {2025},
journal = {Alzheimer's \& Dementia},
doi = {10.1002/alz.70416},
url = {https://doi.org/10.1002/alz.70416}
}RIS
TY - JOUR TI - Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial AU - Jeffrey M. Burns AU - Jill K. Morris AU - Eric D. Vidoni AU - Heather M. Wilkins AU - In‐Young Choi AU - Phil Lee AU - Suzanne L. Hunt AU - Jonathan D. Mahnken AU - William M. Brooks AU - Rebecca J. Lepping AU - Aditi Gupta AU - Russell Esterline AU - Jan Oscarsson AU - Russell H. Swerdlow PY - 2025 JO - Alzheimer's & Dementia DO - 10.1002/alz.70416 UR - https://doi.org/10.1002/alz.70416 ER -
APA
Burns, J. M., Morris, J. K., Vidoni, E. D., Wilkins, H. M., Choi, I., Lee, P., Hunt, S. L., Mahnken, J. D., Brooks, W. M., Lepping, R. J., Gupta, A., Esterline, R., Oscarsson, J., & Swerdlow, R. H. (2025). Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70416
Source records
- crossref · retrieved 2026-09-27T15:00:39.985Z